Literature DB >> 16485345

Epigenetic therapy of cancer: past, present and future.

Christine B Yoo1, Peter A Jones.   

Abstract

The initiation and progression of cancer is controlled by both genetic and epigenetic events. Unlike genetic alterations, which are almost impossible to reverse, epigenetic aberrations are potentially reversible, allowing the malignant cell population to revert to a more normal state. With the advent of numerous drugs that target specific enzymes involved in the epigenetic regulation of gene expression, the utilization of epigenetic targets is emerging as an effective and valuable approach to chemotherapy as well as chemoprevention of cancer.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16485345     DOI： 10.1038/nrd1930

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  415 in total

1.  A structure-activity relationship study of the antimalarial and antileishmanial activities of nonpeptide macrocyclic histone deacetylase inhibitors.

Authors:  William Guerrant; Sandra C Mwakwari; Po C Chen; Shabana I Khan; Babu L Tekwani; Adegboyega K Oyelere
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

2.  Epigenetic changes induced by curcumin and other natural compounds.

Authors:  Simone Reuter; Subash C Gupta; Byoungduck Park; Ajay Goel; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-24       Impact factor: 5.523

Review 3.  DNA methylation topology: potential of a chromatin landmark for epigenetic drug toxicology.

Authors:  Jian Tajbakhsh
Journal:  Epigenomics       Date:  2011-12       Impact factor: 4.778

4.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

Review 5.  Targeting the epigenome with bioactive food components for cancer prevention.

Authors:  Thomas Prates Ong; Fernando Salvador Moreno; Sharon Ann Ross
Journal:  J Nutrigenet Nutrigenomics       Date:  2012-02-22

Review 6.  A decade of exploring the cancer epigenome - biological and translational implications.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

7.  S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth.

Authors:  Jody C Chuang; Steven L Warner; David Vollmer; Hariprasad Vankayalapati; Sanjeev Redkar; David J Bearss; Xiangning Qiu; Christine B Yoo; Peter A Jones
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

Review 8.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

Review 9.  Transcription-factor-mediated epigenetic control of cell fate and lineage commitment.

Authors:  Gary S Stein; Sayyed K Zaidi; Janet L Stein; Jane B Lian; Andre J van Wijnen; Martin Montecino; Daniel W Young; Amjad Javed; Jitesh Pratap; Je-Yong Choi; Syed A Ali; Sandhya Pande; Mohammad Q Hassan
Journal:  Biochem Cell Biol       Date:  2009-02       Impact factor: 3.626

Review 10.  Histone deacetylase inhibitors and transplantation.

Authors:  Ran Tao; Edwin F de Zoeten; Engin Ozkaynak; Liqing Wang; Bin Li; Mark I Greene; Andrew D Wells; Wayne W Hancock
Journal:  Curr Opin Immunol       Date:  2007-08-24       Impact factor: 7.486
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.